Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
In this interview, Jeffrey Cummings speaks to us about the current landscape around antibody therapeutics for Alzheimer’s disease.
At the BNA Festival of Neuroscience, we had the pleasure of speaking with Barry Everitt about his talk on ‘Addiction: a compulsive interplay between drugs, cues and habits’.
In a revolutionary approach, Cognetivity (London, UK) have created a new test for detecting dementia and Alzheimer’s disease by focusing on image cognition and the brain’s ability to analyze visual information.
In this interview, Anders Björklund speaks to us about how we might overcome the current limitations of using stem cell therapies for Parkinson’s disease.
In this interview, we spoke with Viviane Labrie about her research into the vermiform appendix as a possible contributor to Parkinson’s disease.
The BioTechniques editorial team talk to Jenny Straiton about her recent Tech News piece on cerebral organoids and the history of neuroscience.
Whilst at the AD/PD™ conference, we had the pleasure of speaking with Patrik Brundin about his talk on novel therapeutic targets for Parkinson’s disease.
In this interview, we spoke with Alysson Muotri about defining cell maturity in brain organoids and how we could address the challenges with these systems.